The interaction between the effects of semaglutide on participants with and without AF is an interesting observation, given that previous cardiovascular outcome trials have reported no differences in the AF incidence in people receiving GLP-1 RAs compared with placebo.26 This finding must be interpreted with caution given that this was based on only 8 events in those with a past history of AF. The gene discussed is GLP1R; the disease is atrial fibrillation.